Journal article
Thymosin-β4: A key modifier of renal disease
- Abstract:
-
Introduction: There is an urgent need for new treatments for chronic kidney disease (CKD). Thymosin-β4 is a peptide that reduces inflammation and fibrosis and has the potential to restore endothelial and epithelial cell injury, biological processes involved in the pathophysiology of CKD. Therefore, thymosin-β4 could be a novel therapeutic direction for CKD.
Areas covered: Here, we review the current evidence on the actions of thymosin-β4 in the kidn...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 270.5KB)
-
- Publisher copy:
- 10.1080/14712598.2018.1473371
Authors
Funding
Bibliographic Details
- Publisher:
- Taylor and Francis Publisher's website
- Journal:
- Expert Opinion on Biological Therapy Journal website
- Volume:
- 18
- Issue:
- sup1
- Pages:
- 185-192
- Publication date:
- 2018-05-04
- Acceptance date:
- 2018-05-02
- DOI:
- EISSN:
-
1744-7682
- ISSN:
-
1471-2598
- Pmid:
-
29727205
- Source identifiers:
-
853152
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:853152
- UUID:
-
uuid:1618399c-2d94-44d8-bb71-c6630fa237ff
- Local pid:
- pubs:853152
- Deposit date:
- 2019-06-26
Terms of use
- Copyright holder:
- Informa UK, Ltd
- Copyright date:
- 2018
- Notes:
- © 2018 Informa UK, Ltd. This is the accepted manuscript version of the article. The final version is available online from Taylor & Francis at: https://doi.org/10.1080/14712598.2018.1473371
If you are the owner of this record, you can report an update to it here: Report update to this record